# AstraZeneca Plc Calquence Phase III ASCEND trial met primary endpoint

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-calquence-phase-iii-ascend-trial-met-primary-endpoint/412773989
- Published: 2019-05-07T07:33:33+01:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today announced positive results from the Phase III ASCEND trial of Calquence (acalabrutinib)
in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results
showed a statistically-significant and clinically-meaningful improvement in progression-
free survival (PFS) with Calquence monotherapy compared to a combination regimen
of rituximab plus physician’s choice of idelalisib or bendamustine. Importantly,
the safety and tolerability of Calquence was consistent with the known profile.

> **José Baselga, Executive Vice President, R&D Oncology said**: “Calquence is the
> first BTK inhibitor to show benefit in a Phase III trial as a monotherapy compared
> to current standard-of-care combinations used in relapsed or refractory chronic
> lymphocytic leukaemia. We look forward to presenting detailed results at a forthcoming
> medical meeting.”

Within AstraZeneca’s robust development programme for Calquence, ASCEND is the first
of two Phase III CLL trials expected to read out in 2019. The second is ELEVATE-
TN (ACE-CL-007) in treatment-naïve, front-line CLL. Calquence is currently approved
for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL)
in the US, Brazil, the UAE, and Qatar, and is being developed for the treatment 
of CLL and other blood cancers.

**About ASCEND**

ASCEND (ACE-CL-309) is a global, randomised, multicentre, open-label Phase III trial
evaluating the efficacy of Calquence in previously-treated patients with CLL. In
the trial, 310 patients were randomised (1:1) into two groups. Patients in the first
group received Calquence monotherapy (100mg twice daily until disease progression).
Patients in the second group received rituximab plus physician’s choice of idelalisib
or bendamustine.1

The primary endpoint is PFS assessed by an independent review committee (IRC), and
key secondary endpoints include physician-assessed PFS, IRC- and physician-assessed
overall response rate and duration of response, as well as overall survival, patient
reported outcomes and time to next treatment (TTNT).1

**About Calquence**

Calquence (acalabrutinib) was granted accelerated approval by the US Food and Drug
Administration (FDA) in October 2017 for the treatment of adult patients with MCL
who have received at least one prior therapy. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in confirmatory
trials.

Calquence is an inhibitor of Bruton tyrosine kinase (BTK). Calquence binds covalently
to BTK, thereby inhibiting its activity2. In B-cells, BTK signalling results in 
activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis,
and adhesion.

As part of an extensive clinical development programme, AstraZeneca and Acerta Pharma
are currently evaluating Calquence in 26 clinical trials that are company-sponsored.
Calquence is being developed for the treatment of multiple B-cell blood cancers 
including CLL, MCL, diffuse large B-cell lymphoma, Waldenstrom macroglobulinaemia,
follicular lymphoma, and multiple myeloma and other haematologic malignancies. Several
Phase III clinical trials in CLL are ongoing, including ASCEND, ELEVATE-TN, ELEVATE-
RR (ACE-CL-006) evaluating Calquence vs. ibrutinib in previously-treated CLL and
ACE-CL-311 evaluating Calquence in combination with venetoclax and obinutuzumab 
in previously-untreated fit patients with CLL.

**About chronic lymphocytic leukaemia (CLL)**

CLL is the most common type of leukaemia in adults3. In the US, it accounts for 
approximately one in four new cases of leukaemia, with the average age at the time
of diagnosis being approximately 70 years of age4. In CLL, too many blood stem cells
in the bone marrow become abnormal lymphocytes and these abnormal cells have difficulty
fighting infections3. As the number of abnormal cells grows there is less room for
healthy white blood cells, red blood cells and platelets3. This could result in 
anaemia, infection and bleeding3. B-cell receptor signalling through BTK is one 
of the essential growth pathways for CLL.

**About AstraZeneca in haematology**

Leveraging its strength in oncology, AstraZeneca has established haematology as 
one of four key oncology disease areas of focus. The Company’s haematology franchise
includes two US FDA-approved medicines and a robust global development programme
for a broad portfolio of potential blood cancer treatments. Acerta Pharma serves
as AstraZeneca’s haematology research and development arm. AstraZeneca partners 
with like-minded science-led companies to advance the discovery and development 
of therapies to address unmet need.

In October 2018, AstraZeneca and Innate Pharma announced a global strategic collaboration
that included Innate Pharma licensing the US commercial rights of Lumoxiti (moxetumomab
pasudotox-tdfk), and with support from AstraZeneca, will continue EU development
and commercialisation, pending regulatory submission and approval.

**About AstraZeneca in oncology**

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020, and a broad pipeline of small molecules and biologics in development, 
we are committed to advance Oncology as a key growth driver for AstraZeneca focused
on lung, ovarian, breast and blood cancers. In addition to our core capabilities,
we actively pursue innovative partnerships and investments that accelerate the delivery
of our strategy as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
